iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015. The requested “2014 Q4” does not match this filing, which is an annual report covering fiscal 2015 and comparative fiscal 2014.
Business Context
iBio is a biotechnology company commercializing the plant-based iBioLaunch platform for producing vaccines and therapeutic proteins and the iBioModulator platform for enhancing vaccine potency and duration. The company has no marketed products and relies on licensing, collaborations, technology services, equity financing and third-party research and development.
- Most advanced internally developed candidate: IBIO-CFB03 for pulmonary fibrosis, systemic sclerosis and related fibrotic diseases; it remained in preclinical IND-enabling development.
- Pipeline included preclinical therapeutic proteins, enzyme replacements, monoclonal antibodies and vaccines, plus Phase I programs for H1N1, H5N1, malaria, hookworm and anthrax-related candidates.
- Revenue was generated from technology services supporting FioCruz’s yellow-fever vaccine program; the related Fraunhofer subcontractor costs substantially offset revenue.
Financial Performance and Position
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Revenue | $1.851 million | $0.205 million | +803% |
| Research and development expense | $3.495 million | $1.898 million, excluding prior-year credits | +84% adjusted |
| General and administrative expense | $5.022 million | $3.888 million, excluding prior-year adjustments | +29% adjusted |
| Operating loss | $6.666 million | $3.840 million | Higher loss |
| Net loss | $6.625 million | $3.666 million | Higher loss |
| Basic and diluted loss per share | $0.09 loss | $0.06 loss | Worsened |
| Cash flow from operations | $4.725 million used | $4.116 million used | Higher use |
| Cash and cash equivalents | $9.494 million | $3.590 million | +164% |
| Total assets | $12.494 million | $6.494 million | +92% |
| Total liabilities | $1.263 million | $0.395 million | Higher |
| Accumulated deficit | $47.827 million | $41.202 million | Higher deficit |
Reported operating margin was approximately negative 360% and net margin approximately negative 358%, calculated using reported revenue. These margins are distorted because the FioCruz service revenue was matched by substantially equivalent research and development expense and generated no profit. The filing does not disclose outstanding interest-bearing debt; reported liabilities consisted principally of accounts payable and accrued expenses.
Cash Flow, Liquidity and Capitalization
- Operating cash use was $4.725 million; investing cash use was $0.215 million, primarily for intangible assets.
- Financing provided $10.867 million, including $10.0 million from sales of 8,768,806 shares to Aspire Capital and approximately $0.867 million from warrant exercises.
- Management expected $9.5 million of cash at June 30, 2015, together with anticipated Aspire proceeds, to fund operations through June 30, 2016, but stated that additional capital would likely be required thereafter.
- The 2015 Aspire agreement provided an option to sell up to $15.0 million of common stock over 36 months. No shares had been sold under that facility as of the filing date. Potential sales may dilute existing holders and pressure the share price.
- Common shares outstanding increased from approximately 65.6 million at June 30, 2014 to 77.2 million at June 30, 2015. The company also had approximately 9.5 million options and 6.6 million warrants outstanding.
Material Changes Versus Prior Period
- Revenue increased substantially as work under the amended FioCruz agreement resumed, but the associated subcontractor expense resulted in no profit from the program.
- Adjusted research and development spending increased by approximately $1.6 million, primarily due to the revised FioCruz work plan.
- Adjusted general and administrative spending increased by approximately $1.1 million, primarily due to legal fees.
- Prior-year results benefited from approximately $1.9 million of favorable accounting effects from the Fraunhofer settlement and an additional $1.007 million adjustment related to the FioCruz agreement; these items make reported year-over-year comparisons less representative.
- iBio Brazil commenced operations during fiscal 2015 but generated no revenue and incurred approximately $93,000 of general and administrative expense.
Outlook, Risks and Unusual Items
- Management expected continued operating losses and negative operating cash flow and did not provide quantitative revenue or earnings guidance.
- The company remained dependent on additional equity financing, licensing and collaboration revenues. Failure to obtain funding could delay or halt development and commercialization activities and could ultimately threaten continued operations.
- All significant product candidates other than certain completed Phase I vaccine studies remained preclinical or early-stage. No product had received regulatory marketing approval.
- Development depends heavily on third parties, including Fraunhofer, FioCruz, licensees, contract research organizations and external manufacturers.
- Regulatory approval, clinical efficacy and safety, manufacturing scale-up, market acceptance, competition and patent protection remain substantial uncertainties.
- iBio was pursuing litigation against Fraunhofer alleging contractual breaches; the company stated that the outcome could not be predicted. A securities class action had reached an agreement-in-principle to settle, subject to court approval, with expected funding by the company’s insurer.
- The company committed to engage Fraunhofer for at least $3.0 million of work before December 31, 2015; $2.7 million had been engaged by June 30, 2015.
- The financial statements were prepared on a going-concern basis. Management believed available cash and expected financing would support operations through June 30, 2016, subject to assumptions that could prove incorrect.
Investor Verification Checklist
- Verify the company’s post-filing cash burn, remaining liquidity and actual utilization of the 2015 Aspire equity facility.
- Assess dilution from Aspire sales, warrant exercises, outstanding warrants and stock options.
- Track IBIO-CFB03 and partner-sponsored vaccine programs for IND filings, clinical progression and regulatory milestones.
- Confirm whether FioCruz and Fraunhofer work generated cash collections and whether the related receivables and payables were settled.
- Monitor the Fraunhofer litigation and the securities class-action settlement for financial or operational consequences.
- Evaluate whether iBio has secured recurring licensing, milestone or royalty revenue rather than primarily pass-through service revenue.